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Pheochromocytoma: A Frequent Indicator for MEN 2

Claude Calmettes,* Myriam Rosenberg-Gourgin,^ Jean Caron,* and Nicole Feingold*

Pheochromocytoma is a frequent indicator of multiple endocrine neoplasia type 2A (MEN 2A): in the
35 French MEN 2 A families in which a pheochromocytoma occurredfirstin some affected members,
30% of the patients had a pheochromocytoma as the first manifestation constituting 45% of all
patients with pheochromocytomas. Thefindingof a pheochromocytoma is a strong indication for a
search for medullary thyroid carcinoma andfor initiating family screening. (Henry Ford Hosp MedJ
1992:40:276-7)

P

heochromocytoma is frequently asymptomatically associated with medullary thyroid carcinoma (MTC) in multiple
endocrine neoplasia type 2 (MEN 2), Its clinical manifestations
are usually subtle as more than 50% of patients are asymptomatic and normotensive (1,2). Using data of the Groupe d'Etude
des Tumeurs a Calcitonine (GETC), French Medullary Study
Group, we have evaluated the importance of pheochromocytoma presenting as the initial feature of MEN 2.

ing; only a few had been tested for MTC after discovery of the
pheochromocytoma. Pheochromocytoma was diagnosed either
at the same time as the MTC or subsequently but never during
the famdy screening for new cases.
In MEN 2B families, no patients were observed with pheochromocytoma as the initial presenting condition. In apparently
sporadic MEN 2, 62% of the MEN 2A cases and 21% of the
MEN 2B cases had pheochromocytoma as the initial manifestation. Table 2 shows the age at diagnosis of index ca.ses in MEN
2A families and of apparently .sporadic MEN 2A cases.

Material
At present, the GETC lists 113 families with hereditary MEN
2 and 66 apparently sporadic cases. Cases of pheochromocytoma were reported in 62 MEN 2A and in seven MEN 2B famities. From the 62 MEN 2A families, seven have been excluded
from this study because of lack of data. Sixty-six MEN 2 cases
(33 MEN 2A and 33 MEN 2B) have been classified as apparently sporadic because no other cases had yet been found in their
families. A pheochromocytoma was present in 28 of these 33
sporadic MEN 2A patients and in 14 of 33 MEN 2B patients.
For patients presenting initially with a pheochromocytoma, the
MTC diagnosis was made either concomitantly or subsequently
(in five cases the diagnosis was made only by a stimulated calcitonin [CT] procedure).

Data
Incidence of pheochromocytomas as an initial presentation
Pheochromocytoma was the first manifestation in 35 of the
55 selected MEN 2A families (Table 1) (26 index cases and 19
relatives out of 99 MEN patients). The 20 other families without
pheochromocytoma presenting first include 41 patients with
pheochromocytomas. Among index cases, MTC was detected
either clinically or biologically at the same time as or later than
the pheochromocytoma, or by anamnesis of a patient with thyroid tumor.
The relatives who had pheochromocytoma(s) as first manifestations had already undergone adrenal surgery and were discovered by anamnesis of the index case during family screen-
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Discussion
In comparing all MEN 2A families, the proportion of pheochromocytomas is significantly higher in those families in
which a pheochromocytoma was the initial manifestation in
some member (64% versus 47%, P < 0.01).
A pheochromocytoma occurring as the initial manifestation
appears to be a relatively frequent feature of MEN 2A; in the 35
MEN 2A families in which a pheochromocytoma occurred first
in some affected member, 30% of the patients had a pheochromocytoma as the first manifestation, constituting 45% ofall patients with pheochromocytomas. In apparently sporadic MEN
2A, 52% of the patients had pheochromocytomas occurring as
the first manifestation.
A pheochromocytoma occurring first is rare in MEN 2B: no
cases were observed in the MEN 2B families and in only onefourth of the apparently sporadic MEN 2B cases did this occur.
This is likely related to the ease of early diagnosis of MTC. Pheochromocytoma may occur in less aggressive diseases: the age of
diagnosis in cases involving pheochromocytoma is older than
the age of cases without it (20.5 versus (4.5 years, and age at
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Table 1
Number of Pheochromocytomas as the Initial
Presenting Tumors in MEN 2A Families

Pheochromocytomas I st
Total number of
pheochromocytomas
Total patients

Families With
Pheochromocytomas
First (n = 35)

Families Without
Pheochromocytomas
First (n = 20)

45

0

99
156

41
88

death 32.2 versus 19.3 years). The four patients with pheochromocytoma as the first manifestation were 16, 20, 24, and 26
years old at diagnosis. However, the age of discovery of pheochromocytoma is younger in MEN 2B than in MEN 2A.

Conclusion
The frequency of pheochromocytoma as the initial feature of
MEN 2 must nol be ignored; even unilateral pheochromocytoma may be an indicator of MEN 2. The presence of pheochromocytoma is an indication for the patient and the patient's relatives to be studied systematically for MTC as well as to be tested
for von Hippel-Lindau and von Recklinghausen conditions.
The results presented here are a reflection of the evolution of
improved screening procedures available during the past years.
The practice of MTC detection when pheochromocytoma occurs and of pheochromocytoma detection when MTC occurs,
using accurate means of diagnosis and family screening, will
improve the prognosis in these patients and their affected relatives.
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Table 2
Mean Age at Diagnosis for Index MEN 2A Cases
Appearance of
Manifestations
Pheochromocytoma 1st
MTC Ist, pheochromocytoma 2nd
Without pheochromocytoma

MEN 2A Families
Age at Diagnosis

Apparently
Sporadic MEN 2A
Age at Diagnosis

42 yrs (n = 26)
32 yrs (n= 18)
43yrs(n= 11)

44 yrs (n= 15)
33 yrs (n= 13)
33 yrs ( n = l )

Pheochromocytoma is quite variably expressed in MEN 2A
families and even in different branches of the same family. The
factors responsible for this variable expressivity remain to be
clarified.
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